Nancy holds science degrees in Microbiology and Immunology (BSc) and Pharmaceutical Sciences, specialized in Pharmacoeconomics and Pharmacoepidemiology (MSc) from the University of Montreal, Canada. Her professional background includes extensive experience in Canadian pricing and market access of innovative medicines. She holds over 11 years of experience in consultancy, helping pharmaceutical companies across Canada determine the optimal price and market access for new patented drug products. She has led and managed numerous projects, including pricing and market access assessments, regulatory filings, submissions to the Patented Medicine Prices Review Board (PMPRB), formulary listing submissions to the Common Drug Review (CDR), Institut national d’excellence en santé et services sociaux (INESSS), Federal/Provincial/Territorial (F/P/T) public drug plans and private payers. She has provided core strategic insight to drug manufacturers for successful pricing and market access of pharmaceutical products in Canada. She has hands-on experience on a variety of projects with leading pharmaceutical companies and in a broad sphere of therapeutical indications. She also coauthored articles and reports on pricing trends in the pharmaceutical industry.